|
市場調查報告書
美國市場學名藥侵蝕模式
Generics Erosion Patterns in the U.S. Market
|
本報告已在2011年12月21日停止出版。
專家預測2006年至2011年的這段期間，510億美元規模的專利藥將迎接其專利特許期間的結束。專家也表示美國今後將會更加地推廣學名藥的使用。
專門於醫療業界領域進行廣泛調查的美國專業調查公司Decision Resources Inc. (總公司：Massachusetts)，調查分析了美國市場學名藥的侵蝕動向，並有系統地出版了報告書"Generics Erosion Patterns in the U.S. Market" 。
此報告書除了調查學名藥在2002年至2006年期間針對34個專利藥表現出的侵蝕動向、侵蝕模式，也包含例外事項與今後的展望。報告書之內容摘要如下所示。
摘要
說明
方法論
影響學名藥侵蝕的要因
過去學名藥侵蝕模式之例外事項
依配方進行之學名藥侵蝕模式
- 口服、固狀
- 口服、液狀、其他配方（鼻、眼科用液狀、膏狀／棒狀）
- 注入型
其他的調查結果
- 一般口服固型學名藥侵蝕比較
- 對於學名藥製造業者市場的影響
- 一個要素的價格
這樣的模式今後也將持續下去嗎?
表
- 於此報告書所檢證的藥劑及處方
- 此報告書中藥劑分類之定義與界限
圖
- 2002年∼2006年的學名藥侵蝕：口服、固狀、種類1
- 2002年∼2006年的學名藥侵蝕：口服、固狀、種類2
- 2002年∼2006年的學名藥侵蝕：口服、固狀、種類3
- 2002年∼2006年的學名藥侵蝕：口服、液狀
- 2002年∼2006年的學名藥侵蝕：其他處方
- 關於5種藥劑的平均學名藥侵蝕比較（依處方分）
- 2002年∼2006年的學名藥侵蝕：注入型
- 口服固狀藥平均學名藥侵蝕率：2002年∼2006年
- 各處方之學名藥估計數
- 學名藥製造業者對於專利藥市場占有所造成的影響
- 專利藥製造業者如何透過學名藥的子公司來提供全體的處方分享呢：Zithromax
- 專利藥製造業者如何透過學名藥的子公司來提供全體的處方分享呢：Lotensin
- 專利藥製造業者如何透過學名藥的子公司來提供全體的處方分享呢：Celexa
Abstract
Introduction
With an estimated $51 billion of branded drugs coming off patent between 2006
and 2011, both U.S. government insurance plans and private, third-party payers
will promote increased use of generics in the future. In a data-rich report
that employs analyses of 34 branded drugs facing generics competition between
January 2002 and December 2006, we highlight the most effective strategies
employed by pharmaceutical companies in their effort to ward off the threat of
generics competition.
Get the Answers You Need to Shape Your Strategy:
- Several factors determine how quickly a branded product loses market
share. Which of these factors is particularly likely to lead to big paydays
for generics manufacturers? Under what circumstances can the effects of this
critical factor be muted?
- After Zithromax lost patent protection in the United States, Pfi zer
entered the generics market for Zithromax through its own generics subsidiary.
How successfully did Pfi zer' s subsidiary fend off erosion of prescription
share for Zithromax? What lessons can other drug companies take away from Pfi
zer' s strategy?
- Merck employed an unusual pricing strategy in order to retain its market
share for Zocor, after generics entered the market for the branded product.
How successful was Merck in delaying erosion of Zocor' s market share?
- Oral solids typically experience generics erosion at a different rate than
other drug formulations (oral liquids, nasal products, and patches). What
factors account for this difference?
Scope
- Methodology: thirteen fi gures and two tables delineating the data
of generics erosion for 34 drugs between 2002 and 2006.
- Patterns of generics erosion: rates of erosion for oral solids,
oral liquids, and injectables; factors determining rates of erosion; branded
products grouped by their erosion rates.
- Exceptions to traditional generics erosion: drugs that did not
follow traditional patterns of erosion.
- Outlook: Data from the Centers for Medicare & Medicaid Services
(CMS); pending U.S. legislation.
Selection of Brand Products Facing Generic Entry, 2002-2006
- Accupril
- Agrylin
- Axid
- Biaxin
- Celexa
- Cipro
- Difl ucan
- Duragesic
- Effexor
- Flonase
- Floxin/Occufl ox
- Glucophage XR
- Glucotrol XL
- Glucovance
- Lotensin
- Metaglip
- Mobic
- Monopril
- Novantrone
- Paraplatin
- Paxil
- Pravachol
- Proscar
- Retrovir
- Rocephin
- Romazicon
- Tambocor
- Ultram
- Zaditor
- Zestril/Prinivil
- Zithromax
- Zocor
- Zofran
- Zoloft
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- Methodology
- Factors Infl uencing Generics Erosion
- Exceptions to Traditional Generics Erosion Patterns
- Patterns of Generics Erosion by Formulation
- Oral Solids
- Oral Liquids and Other Formulations (Nasal, Ophthalmic Liquids,
Patches/Discs)
- Injectables
- Other Findings
- Comparison of Average Oral Solid Generics Erosion
- Market Infl uence of Generics Manufacturers
- Price As a Factor
- Will These Patterns Continue?
Tables
- 1. Drugs and Formualtions Examined in this Report
- 2. Defi nitions and Parameters of Drug Groupings in this Report
Figures
- 1. Generics Erosion for Selected Products, 2002-2006: Oral Solids, Group 1
- 2. Generics Erosion for Selected Products, 2002-2006: Oral Solids, Group 2
- 3. Generics Erosion for Selected Products, 2002-2006: Oral Solids, Group 3
- 4. Generics Erosion for Selected Products, 2002-2006: Oral Liquids
- 5. Generics Erosion for Selected Products, 2002-2006: Other Formulations
- 6. Comparison of Average Generics Erosion (by Formulation) for Five Drugs
- 7. Generics Erosion for Selected Products, 2002-2006: Injectables/IVs
- 8. Average Generics Erosion Rates of Oral Solids, 2002-2006
- 9. Estimated Average Number of Generics Competitors by Formulation
- 10. The Effect of Generics Manufacturers on Brand Market Share Volume
- 11. How Brand Manufacturers Can Maintain Total Prescription Share Through
Generics Subsidiaries: Zithromax
- 12. How Brand Manufacturers Can Maintain Total Prescription Share Through
Generics Subsidiaries: Lotensin
- 13. How Brand Manufacturers Can Maintain Total Prescription Share Through
Generics Subsidiaries: Celexa
|
